News

August 17, 2005 - Cyprotex enters significant long-term contract with Sepracor

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has entered into a significant long-term contract for Cyprotex's integrated Cloe offering with the major US-based pharmaceutical company, Sepracor Inc.

Commenting on the agreement, Robert Morrisson Atwater, Chief Executive Officer of Cyprotex PLC, said: "This is Cyprotex's first major US partnership which shows that our technologies, expertise and general approach are attracting a wider audience. This deal is clear demonstration that Cyprotex is gaining well deserved recognition as a valuable partner in drug discovery."

For further information:

Cyprotex PLC
Robert Morrisson Atwater, Chief Executive Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Media Enquires:

Abchurch Communications
Heather Salmond / Samantha Robbins
Tel: +44 (0) 20 7398 7700
samantha.robbins@abchurch-group.com
www.abchurch-group.com